

Ministry of Health

# Drugs and Devices Division

Drug Submission Status

Report for June 2021

## Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

<b>Manufacturer</b>	<b>Product</b>	<b>Reference Product</b>	<b>Generic Name</b>	<b>Strength</b>	<b>Dosage Form</b>	<b>DIN</b>
Apotex Inc.	Apo-Doxycycline MR	Aprilion	DOXYCYCLINE	40mg	modified-release capsule	02512645
Jamp Pharma Corporation	JAMP Eletriptan	Relpax	ELETRIPTAN	20mg	FC tablet	02493683
Jamp Pharma Corporation	JAMP Eletriptan	Relpax	ELETRIPTAN	40mg	FC tablet	02493691
Sandoz Canada Inc.	Sandoz Deferasirox (Type J)	Jadenu	DEFERASIROX	90 mg	tablet	02489899
Sandoz Canada Inc..	Sandoz Deferasirox (Type J)	Jadenu	DEFERASIROX	180 mg	tablet	02489902

Sandoz Canada Inc.	Sandoz Deferasirox (Type J)	Jadenu	DEFERASIROX	360 mg	tablet	02489910
Sanis Health Inc.	Cetirizine	Reactine	CETIRIZINE HYDROCHLORIDE	20 mg	tablet	02515695
Jamp Pharma Corporation	Jamp Pirfenidone	Esbriet	PIRFENIDONE	267 mg	capsule	02509938
Jamp Pharma Corporation	Jamp Paroxetine Tablets	Paxil	PAROXETINE HCL	10 mg	tablet	02507773